4-溴-2-(溴甲基)-1-甲氧基苯 | 184970-28-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-(溴甲基)-1-甲氧基苯
• 中文别名: 4-溴-2-溴甲基-1-甲氧基苯
• 英文名称: 4-bromo-2-(bromomethyl)-1-methoxybenzene
• CAS: 184970-28-3
• 化学式: C₈H₈Br₂O
• mdl: MFCD07324845
• 分子量: 279.959
• InChiKey: MZJDFNYHPWAVQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P264,P270,P271,P280,P303+P361+P353,P304+P340,P305+P351+P338,P310,P330,P331,P363,P403+P233,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H314

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-(bromomethyl)-1-methoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-(bromomethyl)-1-methoxybenzene
CAS number: 184970-28-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8Br2O
Molecular weight: 280.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-(溴甲基)-1-甲氧基苯 在 2,2'-联吡啶 、 copper(l) iodide 、 magnesium 、 1,2-二溴乙烷 作用下， 以 乙醚 、 苯 为溶剂， 反应 1.5h， 生成 4'-甲氧基-3',5-二-2-丙烯基-(1,1'-联苯)-2-醇
  参考文献：
  名称：

  A concise synthesis of 4′-O-methyl honokiol

  摘要：

  A concise and protecting group free synthesis of the naturally occurring neolignan 4'-O-methyl honokiol is developed. The key biaryl bond is constructed by 1,2-addition of an aryl Grignard reagent to a dienone followed by rearrangement. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2011.03.031
• 作为产物：
  描述：

  5-溴-2-甲氧基苯甲醇 在 五溴化磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以92%的产率得到4-溴-2-(溴甲基)-1-甲氧基苯
  参考文献：
  名称：

  活细胞溶酶体发光的铕配合物的合成与评价

  摘要：

  研究了一组四种带有扩展芳基-炔基吡啶发色团的发光 Eu III配合物，其吸收和发射光谱响应显示出非常不同的 pH 依赖性行为。对于含蛋白质溶液中 p K a值为 6.45 和 6.20 的两种配合物，质子化后发射寿命显着增加。通过改变信号采集期间的选通时间，可以优化“开启”强度比，并且在 pH 8 和 4 之间测量到 250 到 1330 之间的增强因子。表现最佳的探针显示出对浓度没有显着的发射依赖性内源性阳离子、还原剂和血清白蛋白。在活细胞成像研究中对其进行了检查，以监测时间依赖性溶酶体酸化，在 NIH-3T3 细胞中，由于酸化而观察到的图像亮度增加了 50 倍。

  DOI：

  10.1002/chem.202003992

文献信息

• Melanocortin-4 receptor binding compounds and methods of use thereof
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040082779A1

  公开（公告）日：2004-04-29

  Provided are MC4-R binding compounds of the formula XVII: 1 wherein L 2 is a linker group, and P 1 , P 2 , P 3 , P 4 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.

  提供了具有以下化学式XVII的MC4-R结合化合物： 其中L2是连接基团，P1、P2、P3、P4、Z1、Z2、Z3、Z4、Z5、t、s和R如规范中所述。还提供了使用这些化合物治疗与MC4-R相关疾病的方法，例如与体重减轻相关的疾病。
• Direct Oxidative Conversion of Methylarenes into Aromatic Nitriles
  作者：Daisuke Tsuchiya、Yuhsuke Kawagoe、Katsuhiko Moriyama、Hideo Togo

  DOI：10.1021/ol401906q

  日期：2013.8.16

  successfully converted into the corresponding aromatic nitriles in good to moderate yields by the treatment with NBS or DBDMH in the presence of a catalytic amount of AIBN or BPO, followed by the reaction with molecular iodine in aq NH3 in a one-pot procedure. The present reaction is a useful and practical transition-metal-free method for the preparation of aromatic nitriles from methylarenes.

  各种methylarenes的通过在AIBN或BPO催化量的存在下用NBS或DBDMH治疗成功转化成相应的芳族腈以优良至适中的产率，然后用分子碘的反应是在水溶液NH 3在一-pot过程。本反应是用于从甲基芳烃制备芳族腈的有用且实用的无过渡金属的方法。
• One-Pot Transformation of Methylarenes into Aromatic Aldehydes under Metal-Free Conditions
  作者：Masayuki Tabata、Katsuhiko Moriyama、Hideo Togo

  DOI：10.1002/ejoc.201402015

  日期：2014.6

  of the transformation of benzylic bromides into the corresponding aromatic aldehydes by treatment with N-methylmorpholine N-oxide, various methylarenes were treated either with DBDMH in the presence of AIBN in acetonitrile at reflux (Method A) or with NBS in CCl4 under irradiation with a tungsten lamp at 30 °C (Method B), followed by treatment with N-methylmorpholine N-oxide to provide aromatic aldehydes

  在通过用 N-甲基吗啉 N-氧化物处理将苄基溴转化为相应的芳香醛的研究的基础上，在 AIBN 的存在下，在回流的乙腈中用 DBDMH 或用 NBS 处理各种甲基芳烃CCl4 在 30 °C 下用钨灯照射（方法 B），然后用 N-甲基吗啉 N-氧化物处理以提供高产率的芳香醛。这些方法可用于在无毒性较小的试剂和过渡金属的条件下将甲基芳烃一锅法转化为芳香醛。
• NK-1 AND SEROTONIN TRANSPORTER INHIBITORS
  申请人：Degnan P. Andrew

  公开号：US20070249607A1

  公开（公告）日：2007-10-25

  The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

  这项发明涵盖了公式I的化合物，包括药用盐，它们的药物组合物，以及它们在治疗与过多或不平衡的速激肽或血清素或两者都有关的疾病中的用途。
• Glycine Chroman-6-Sulfonamides for Use as Inhibitors of Diacylglycerol Lipase
  申请人：Hu Shuanghua

  公开号：US20110207772A1

  公开（公告）日：2011-08-25

  The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.

  本公开涉及一般可抑制DAGLα和/或β活性的化合物，包括这些化合物的组合物，以及抑制DAGLα和/或β活性的方法。